Single-Center Cohort of Pediatric Patients with High-Risk Neuroblastoma Receiving Immunotherapy., PMID:40507305
Case Report: Locally invasive thyroid metastases from renal cell carcinoma: surgery after neoadjuvant therapy., PMID:40502628
Enfortumab vedotin induced interstitial lung disease: A first case report with pathological evidence from transbronchial lung cryobiopsy., PMID:40496844
The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system., PMID:40491923
Clinical Outcomes in Patients With Muscle-Invasive Urothelial Carcinoma Treated With Nivolumab., PMID:40489108
Organ-Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study., PMID:40488227
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)., PMID:40468805
Immune-mediated enterocolitis is associated with immune checkpoint inhibitors: A pharmacovigilance study from the FDA Adverse Event Reporting System (FAERS) database., PMID:40465755
Personalized drug stratification using endoscopic samples to assess ex vivo gastric cancer tissue susceptibility to chemotherapy and immune checkpoint inhibitors., PMID:40465055
Cutaneous adverse effects of combination epidermal growth factor receptor inhibitor and immune checkpoint inhibitor cancer therapy., PMID:40455297
The combination of body mass index and serum creatinine levels predicts survival in patients with Hodgkin lymphoma treated with nivolumab in the CheckMate 205 study., PMID:40452181
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study., PMID:40449497
Research hotspots and trends in lung cancer immunotherapy are revealed by a bibliometric study spanning the years 2004 to 2024., PMID:40448551
Ultrafast Microdroplet Digestion of Antibodies with Fc-Silencing Mutations., PMID:40438971
Phase-Ib dose-finding and pharmacokinetic trial of metformin combined with nivolumab for refractory/recurrent solid tumors., PMID:40434511
Correlation Between Body Mass Index and Clinical Outcomes in Advanced Renal Cell Carcinoma Patients., PMID:40425321
Using liquid biopsies to guide treatment and monitor response in BRAF V600E positive adenocarcinoma of unknown primary., PMID:40425210
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)., PMID:40423789
Multisystem immune-related adverse reactions with immune checkpoint inhibitors., PMID:40421943
Adjuvant Immunotherapy in Microsatellite Instability-High Colon Cancer: A Literature Review on Efficacy, Challenges, and Future Directions., PMID:40415356
[ARTIFICIAL INTELLIGENCE-ASSISTED LITERATURE REVIEW: A CASE STUDY IN FUMARATE HYDRATASE-DEFICIENT RENAL CELL CARCINOMA]., PMID:40413584
Intrathecal nivolumab and IL-2 for treatment of leptomeningeal metastases in EGFR-mutated lung adenocarcinoma., PMID:40412102
Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1/PD-L1., PMID:40411581
A Case of Nivolumab-Related Myasthenia Gravis With Pretreatment Positive Anti-Acetylcholine Receptor Antibodies, and a Literature Review., PMID:40409987
A treatment-related death predictive score for treatment-naïve advanced non-small cell lung cancer., PMID:40409025
Real-World Efficacy and Safety of Anti-PD-1 Antibody Therapy for Patients With Advanced Cutaneous Squamous Cell Carcinoma: A Single-Center Retrospective Study in Japan., PMID:40407151
Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Systematic Review., PMID:40403200
Guillain-Barre Syndrome-Like Polyneuropathy Induced by Immune Checkpoint Inhibitors: A Case Report., PMID:40396801
Real-world efficacy and safety of nivolumab and ipilimumab in metastatic renal cell carcinoma: a Polish multicenter study., PMID:40391586
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial., PMID:40389374
Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study., PMID:40389373
Perioperative immunotherapy strategies for resectable non-small cell lung cancer., PMID:40386901
[Renal injury during combination immunotherapy (ipilimumab + nivolumab) in patients with metastatic renal cell cancer who previously underwent nephrectomy]., PMID:40377638
Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring., PMID:40375301
A Fatal Case of Immune Checkpoint Inhibitor-Associated Myocarditis with Severe Right Ventricular Failure., PMID:40368772
Immune Checkpoint Inhibitors and Antibody-Drug Conjugates in Urothelial Carcinoma: Current Landscape and Future Directions., PMID:40361519
Prospective Multi-Institutional Observational Study of Retreatment with Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1/PD-L1 Plus Chemotherapy: NJLCG (North Japan Lung Cancer Group) Trial 1901., PMID:40361477
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)., PMID:40360544
[A Case of Advanced Gastric Cancer with Cervical Lymph Node Metastasis Responding to SOX+Nivolumab and Treated with Conversion Surgery]., PMID:40360411
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer., PMID:40359708
Promising Treatment Strategy for Primary Malignant Melanoma of the Esophagus by Radical Esophagectomy and Nivolumab as Adjuvant Therapy: A Case Report., PMID:40356806
An Extremely Rare Case of Immune Checkpoint Inhibitors-Related Hypoparathyroidism and a Critical Literature Review., PMID:40356787
Relationships between surface tensiometry properties and fluorescence intensity of dark and light exposed monoclonal antibody Nivolumab/Opdivo® by using the contact angle method: A pilot study., PMID:40349925
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial., PMID:40349714
The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab., PMID:40347721
Virtual Clinical Trial Reveals Significant Clinical Potential of Targeting Tumor-Associated Macrophages and Microglia to Treat Glioblastoma., PMID:40347051
The emerging role of lymphocyte-activation gene 3 targeting in the treatment of solid malignancies., PMID:40344213
Nivolumab- and ipilimumab-induced myositis, myasthenia gravis, and myocarditis in a patient with metastatic melanoma., PMID:40343457
A multicenter, prospective, observational study of nivolumab readministration for advanced gastric cancer (NIVO RETURNS)., PMID:40336472
Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy., PMID:40331873
For research use only. Not for human or drug use.
